Abstract
A small molecule that could bind selectively to and then react chemoselectively with a non-enzyme protein in a complex biological fluid, such as blood, could have numerous practical applications. Herein, we report a family of designed stilbenes that selectively and covalently modify the prominent plasma protein transthyretin in preference to more than 4,000 other human plasma proteins. They react chemoselectively with only one of eight lysine ε-amino groups within transthyretin. The crystal structure confirms the expected binding orientation of the stilbene substructure and the anticipated conjugating amide bond. These covalent transthyretin kinetic stabilizers exhibit superior amyloid inhibition potency compared to their noncovalent counterparts, and they prevent cytotoxicity associated with amyloidogenesis. Though there are a few prodrugs that, upon metabolic activation, react with a cysteine residue inactivating a specific non-enzyme, we are unaware of designed small molecules that react with one lysine ε-amine within a specific non-enzyme protein in a complex biological fluid.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Savi, P. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891–896 (2000).
Estebanez-Perpina, E. et al. Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol. Endocrinol. 21, 2919–2928 (2007).
Guo, F. et al. Breaking the one antibody-one target axiom. Proc. Natl. Acad. Sci. USA 103, 11009–11014 (2006).
Cohen, E. et al. Opposing activities protect against age-onset proteotoxicity. Science 313, 1604–1610 (2006).
Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
Balch, W.E., Morimoto, R.I., Dillin, A. & Kelly, J.W. Adapting proteostasis for disease intervention. Science 319, 916–919 (2008).
Johnson, S.M. et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911–921 (2005).
Westermark, P., Sletten, K., Johansson, B. & Cornwell, G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 87, 2843–2845 (1990).
Coelho, T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr. Opin. Neurol. 9, 355–359 (1996).
Jacobson, D.R. et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 336, 466–473 (1997).
Sekijima, Y. et al. The biological and chemical basis for tissue selective amyloid disease. Cell 121, 73–85 (2005).
Holmgren, G. et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341, 1113–1116 (1993).
Klabunde, T. et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 7, 312–321 (2000).
Monaco, H.L., Rizzi, M. & Coda, A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268, 1039–1041 (1995).
Wojtczak, A., Luft, J. & Cody, V. Mechanism of molecular recognition. Structural aspects of 3,3′-diiodo-L-thyronine binding to human serum transthyretin. J. Biol. Chem. 267, 353–357 (1992).
Colon, W. & Kelly, J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654–8660 (1992).
Liu, K. et al. A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat. Struct. Biol. 7, 754–757 (2000).
Jiang, X. et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40, 11442–11452 (2001).
Hammarstrom, P., Wiseman, R.L., Powers, E.T. & Kelly, J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 713–716 (2003).
Hammarstrom, P., Schneider, F. & Kelly, J.W. Trans-suppression of misfolding in an amyloid disease. Science 293, 2459–2462 (2001).
Hurshman, A.R., White, J.T., Powers, E.T. & Kelly, J.W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43, 7365–7381 (2004).
Hurshman Babbes, A.R., Powers, E.T. & Kelly, J.W. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: The relationship between stability and amyloidosis. Biochemistry 47, 6969–6984 (2008).
Adamski-Werner, S.L., Palaninathan, S.K., Sacchettini, J.C. & Kelly, J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 47, 355–374 (2004).
Johnson, S.M., Connelly, S., Wilson, I.A. & Kelly, J.W. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J. Med. Chem. 51, 6348–6358 (2008).
Johnson, S.M. et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 48, 1576–1587 (2005).
Miroy, G.J. et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 93, 15051–15056 (1996).
Oza, V.B. et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 45, 321–332 (2002).
Razavi, H. et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem. Int. Ed. Engl. 42, 2758–2761 (2003).
Wiseman, R.L. et al. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J. Am. Chem. Soc. 127, 5540–5551 (2005).
Foss, T.R. et al. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J. Mol. Biol. 347, 841–854 (2005).
Foss, T.R., Wiseman, R.L. & Kelly, J.W. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 44, 15525–15533 (2005).
Johnson, S.M., Connelly, S., Wilson, I.A. & Kelly, J.W. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J. Med. Chem. 51, 260–270 (2008).
Petrassi, H.M., Klabunde, T., Sacchettini, J.C. & Kelly, J.W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J. Am. Chem. Soc. 122, 2178–2192 (2000).
Purkey, H.E. et al. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem. Biol. 11, 1719–1728 (2004).
Baures, P.W., Oza, V.B., Peterson, S.A. & Kelly, J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem. 7, 1339–1347 (1999).
Green, N.S., Palaninathan, S.K., Sacchettini, J.C. & Kelly, J.W. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J. Am. Chem. Soc. 125, 13404–13414 (2003).
Miller, S.R., Sekijima, Y. & Kelly, J.W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab. Invest. 84, 545–552 (2004).
Burgi, H.B., Dunitz, J.D., Lehn, J.M. & Wipff, G. Stereochemistry of reaction paths at carbonyl centers. Tetrahedron 30, 1563–1572 (1974).
Hammarstrom, P., Jiang, X., Deechongkit, S. & Kelly, J.W. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry 40, 11453–11459 (2001).
Purkey, H.E., Dorrell, M.I. & Kelly, J.W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. USA 98, 5566–5571 (2001).
Lashuel, H.A., Wurth, C., Woo, L. & Kelly, J.W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38, 13560–13573 (1999).
Baures, P.W., Peterson, S.A. & Kelly, J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 6, 1389–1401 (1998).
Zhang, Q. & Kelly, J.W. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry 42, 8756–8761 (2003).
Reixach, N. et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA 101, 2817–2822 (2004).
Reixach, N. et al. Cell based screening of inhibitors of transthyretin aggregation. Biochem. Biophys. Res. Commun. 348, 889–897 (2006).
O'Brien, J., Wilson, I., Orton, T. & Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267, 5421–5426 (2000).
Wojtczak, A., Cody, V., Luft, J.R. & Pangborn, W. Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 angstrom resolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites. Acta Crystallogr. D Biol. Crystallogr. 57, 1061–1070 (2001).
Marinec, P.S. et al. FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. Proc. Natl. Acad. Sci. USA 106, 1336–1341 (2009).
Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
Storoni, L.C., McCoy, A.J. & Read, R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60, 432–438 (2004).
Acknowledgements
We acknowledge US National Institutes of Health grants DK46335 to J.W.K. and CA58896 and AI42266 to I.A.W. We also thank the Skaggs Institute for Chemical Biology and the Lita Annenberg Hazen Foundation for financial support. Technical support from M. Saure and G. Dendle is greatly appreciated. We are grateful to C. Fearns for carefully reading and editing the manuscript. We thank the General Clinical Research Center of the Scripps Research Institute for providing human blood. The authors also acknowledge R. Stanfield, X. Dai, S. Yoon, R. Xu and D. Ekiert for assisting with X-ray data collection. X-ray diffraction data were collected at GM/CA-CAT 23-IDB beamline at the Advanced Photon Source, Argonne National Laboratory. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Basic Energy Sciences, under contract number W-31-109-Eng-38.
Author information
Authors and Affiliations
Contributions
S. Choi performed the chemical syntheses and all biochemical assays and wrote the majority of the paper. S. Connelly performed the crystallization, crystallographic structure determination and the structural analyses and wrote the crystallography section of the paper. N.R. carried out all the cell-based assays and wrote that section of the manuscript. I.A.W. supervised the crystallographic work and edited the manuscript. J.W.K. supervised the chemical biology and edited the paper.
Corresponding author
Ethics declarations
Competing interests
J.W.K. is a founder, shareholder and paid consultant for Foldrx Pharmaceuticals, Inc., a biotechnology company that specializes in the discovery and development of drug therapies for transthyretin amyloidoses.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Scheme 1, Supplementary Figures 1–14 and Supplementary Table 1 (PDF 629 kb)
Rights and permissions
About this article
Cite this article
Choi, S., Connelly, S., Reixach, N. et al. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nat Chem Biol 6, 133–139 (2010). https://doi.org/10.1038/nchembio.281
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.281
This article is cited by
-
Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects
Nature Communications (2022)
-
A proteome-wide atlas of lysine-reactive chemistry
Nature Chemistry (2021)
-
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Journal of Hematology & Oncology (2020)
-
Chemoselective and photocleavable cysteine modification of peptides and proteins using isoxazoliniums
Communications Chemistry (2019)
-
Global profiling of lysine reactivity and ligandability in the human proteome
Nature Chemistry (2017)